Methylnaltrexone bromide

Drug Profile

Methylnaltrexone bromide

Alternative Names: Methyl-naltrexone hydrobromide; Methylnaltrexonium; MNTX; MNTX 302; MOA-728; MRZ 2663BR; MRZ-2663; N-methylnaltrexone bromide; Naltrexone MB; Naltrexone methobromide; Naltrexone methylbromide; Naltrexonium methiodide; ONO-3849; Quaternary ammonium naltrexone; Relistor; Relistor Oral

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator University of Chicago
  • Developer Ono Pharmaceutical; Progenics Pharmaceuticals; Salix Pharmaceuticals
  • Class Morphine derivatives; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Postoperative ileus
  • New Molecular Entity Yes
  • Available For Licensing Yes - Constipation

Highest Development Phases

  • Marketed Constipation
  • Discontinued Postoperative ileus; Urination disorders

Most Recent Events

  • 06 Sep 2016 Launched for Constipation in USA (PO)
  • 19 Jul 2016 Registered for Constipation in USA (PO)
  • 25 May 2016 No development reported - Phase-II for Constipation in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top